CompletedNCT00191698
Atomoxetine compared with placebo for oppositional symptoms in children with ADHD
About this title
Read the official source — NCT00191698Medication studyAges 6–12Multiple countries
Understand this study
Who was this study for?
Listed age limits: 6 years to 12 years.
- Listed locations
- Wallsend and 15 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateDecember 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 226
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Australia, United Kingdom, Belgium, ...
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT00191698
- Official title
Show the full official title
A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride and Placebo in Child and Adolescent Outpatients With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Wallsend, Australia · Parkville, Australia · Antwerp, Belgium
13 more locations
- Brussels, Belgium
- Leuven, Belgium
- Risskov, Denmark
- Helsinki, Finland
- Mannheim, Germany
- Ulm, Germany
- Nijmegen, Netherlands
- Utrecht, Netherlands
- Barcelona, Spain
- Tarrasa, Spain
- Pamplona, Spain
- Dundee, United Kingdom
- Edinburgh, United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including atomoxetine hydrochloride and placebo.
Who was this study for?
Listed age limits: 6 years to 12 years.
Want to explore more studies?
Explore studiesRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...